Today, the term MSC describes a class of cells that have historically been known as mesenchymal stem cells, mesenchymal stromal cells, and medicinal signaling cells, among other names. The clinical utility of MSCs is primarily attributed to their key biological properties, which include: [Read more…]
Winner of the “Biotherapies and Bioproduction” Call for Projects Under the France 2030 plan, EVerZom Receives €3M in Government Funding to Industrialize its Exosome Bioproduction Technology
Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the “Biotherapies and Bioproduction of Innovative Therapies” call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. [Read more…]
L2 Bio Seeks Principal Investigators for FDA-Approved Phase 2B Clinical Trial of Adipose-Derived Stem Cell Treatment for Crohn’s Disease
HENDERSON, NV – June 12, 2025, www.L2Bio.com – L2 Bio, is the clear leader in adipose-derived stem cell banking. L2 Bio is the only AD-Stem Cell Banking company with an FDA Approved Investigational New Drug. L2 is actively recruiting qualified Principal Investigators for its recently FDA-approved Phase 2B clinical trial. This groundbreaking study will investigate a novel intravenous (IV) delivery of adipose-derived stem cells (ADSCs or ASCs) for the treatment of Crohn’s Disease utilizing autologous or first-degree blood relative sourced Adipose Derived Mesenchymal Stem Cells (AD-MSCs). A simple, virtually painless, 15-minute procedure from the subject or donor is likely to produce enough stem cells to treat the subject for the duration of the trial and likely the remainder of their life if necessary. [Read more…]
Amniotic Stem Cells: An Extension of the Cord Blood Banking Model
Amniotic stem cells, which can be sourced from the amniotic fluid or the placenta after a live, healthy birth, possess a unique blend of multipotency and lack of tumorigenicity. In an extension of the cord blood banking model, these cells may improve outcomes where long-term cell survival and functionality is important. Recently, I had the honor of interview Dr. Todd McAllister, Executive Director at the Amnion Foundation, a non-profit organization with the mission to build a genetically diverse public cell bank that can provide an immunological match to the majority of the population.
In this interview, we discuss the Amnion Foundation’s vision, research and clinical approach, scale-out strategy, and interest in joint partnerships that will support greater utilization of amniotic stem cells. It is captivating to get an insider look at the Amnion Foundation, a non-profit that is introducing a new extension to the traditional cord blood and tissue banking market.
As the cord blood banking market matures and consolidates and diversifies into new types of perinatal stem cell storage, the Amnion Foundation will be uniquely positioned to advise cord blood banks on how to integrate amniotic stem cell banking into their service portfolio.
Regenexx – Dr. Chris Centeno on the Orthopedic Applications of MSCs
Regenexx is a U.S. company specializing in orthopedic applications of stem cells that was founded by Dr. Chris Centeno. Dr. Centeno is an international expert in regenerative medicine and the clinical use of mesenchymal stem cells (MSCs) in orthopedic applications. His Regenexx clinic in Denver, Colorado, incorporates a variety of regenerative approaches, drawing patients from all over the U.S. who are seeking innovative, non-surgical treatments. [Read more…]
- « Previous Page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- …
- 334
- Next Page »